← All trials
NCT07302516
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 25, 2025
- Primary completion
- Dec 31, 2028
- Completion date
- Dec 31, 2029
- First posted
- Dec 24, 2025
- Last posted
- Dec 24, 2025
- Enrollment
- 636
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Qilu Pharmaceutical Co., Ltd.Lead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.